



## Finances and funding At a glance



### Income 2020/21



### Growth



The ICR's income rose by **£10.2 million** in 2020/21, an increase of **eight per cent** over the previous financial year.

### Income

# £142m

The Institute of Cancer Research, London, had a total income in 2020/21 of **£142 million**.



We received **£69.4 million** – around **49 per cent** of our income – from peer-reviewed research grants and industrial collaboration. Around **39 per cent** of our income came from Cancer Research UK, **18 per cent** from industrial collaborations, **13 per cent** from Breast Cancer Now, **four per cent** from Wellcome and **two per cent** from the Medical Research Council.



As a membership institution of the University of London, the ICR received **20 per cent** of its income from the Office for Students and UK Research and Innovation.

From a total of **£28.3 million**, **£21.1 million** funding for research, **£1.1 million** for teaching and **£2.3 million** capital funding.



We received **£23.8 million** – around **17 per cent** of our income – from royalties.



The ICR also received a total of **£12.7 million**, around **nine per cent** of our total income, in legacies and donations, raised through our Development Office. Some **£5 million** of the total came from legacies and **£7.7 million** from donations.



The increase in income was mainly attributable to growth in research grants and contracts of **£10.4 million**, reflecting the benefits of keeping our research going through the year, following the closure of our laboratory buildings for two months in 2019/20.

### Expenditure



The ICR's total expenditure in 2020/21 was **£124.6 million**, an increase of **£23 million** compared with 2019/20.



We spent a total of **£95.6 million**, or **96 per cent** of our total spend, on research activity. We spent **76 per cent** of our total spend on the direct costs of research and **19 per cent** on the support costs of research.